Keyword Analysis & Research: sgn33a

nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC6723634/

WEBAug 20, 2019 · Vadastuximab Talirine (SGN33A) and IMGN779 Other ADCs that target CD33 have been developed and are being actively investigated for AML therapy. Early … Author: Brent A. Williams, Arjun Law, Judit Hunyadkurti, Stephanie Desilets, Jeffrey V. Leyton, Jeffrey V. L... Publish Year: 2019

Author: Brent A. Williams, Arjun Law, Judit Hunyadkurti, Stephanie Desilets, Jeffrey V. Leyton, Jeffrey V. L...

Publish Year: 2019

DA: 67 PA: 26 MOZ Rank: 99

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723634/

DA: 67 PA: 92 MOZ Rank: 90

clinicaltrials.gov:443

https://classic.clinicaltrials.gov:443/ct2/show/NCT01902329

WEBJul 18, 2013 · Brief Summary: This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered as a single agent and in combination with a … Actual Enrollment : 195 participants Intervention Model: Parallel Assignment Allocation: Non-Randomized Study Type : Interventional (Clinical Trial)

Actual Enrollment : 195 participants

Intervention Model: Parallel Assignment

Allocation: Non-Randomized

Study Type : Interventional (Clinical Trial)

DA: 36 PA: 12 MOZ Rank: 10

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331698/

DA: 87 PA: 90 MOZ Rank: 59

nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC6331698/

WEBJul 24, 2018 · Vadastuximab talirine (SGN33A) is an ADC containing the lintuzumab antibody and a pyrrolobenzodiazepine dimer. Early clinical trials in relapsed AML have … Author: Mohammed Gbadamosi, Soheil Meshinchi, Jatinder K Lamba DOI: 10.2217/fon-2018-0325 Publish Year: 2018 Publication: Future Oncol. 2018 Dec; 14(30): 3199-3213.

Author: Mohammed Gbadamosi, Soheil Meshinchi, Jatinder K Lamba

DOI: 10.2217/fon-2018-0325

Publish Year: 2018

Publication: Future Oncol. 2018 Dec; 14(30): 3199-3213.

DA: 80 PA: 99 MOZ Rank: 43

nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC8143531/

WEBMay 10, 2021 · Monoclonal antibodies treatments include naked antibodies against AML surface antigens such as CD33 (e.g. lintuzumab) or CD38 (e.g. daratumumab), … Author: Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marin... Publish Year: 2021

Author: Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marin...

Publish Year: 2021

DA: 23 PA: 1 MOZ Rank: 63

openaccessgovernment.org:443

https://www.openaccessgovernment.org:443/cd33-directed-therapy/47313/

WEBSep 12, 2018 · Vadastuximab talirine (SGN33A) is generated through conjugation the CD33-directed antibody lintuzumab and a …

DA: 5 PA: 96 MOZ Rank: 100

nih.gov:443

https://pubmed.ncbi.nlm.nih.gov:443/29206680/

WEBMonoclonal antibodies in AML therapy include naked antibodies against AML surface antigens such as CD33 (e.g. lintuzumab) or CD38 (e.g. daratumumab), antibodies …

DA: 27 PA: 90 MOZ Rank: 77

astctjournal.org:443

https://www.astctjournal.org:443/article/S1083-8791(14)00990-2/fulltext

WEBBackground. CD33 is expressed on the surface of myeloblasts in ∼90% of AML, representing a promising, clinically validated target. SGN–CD33A is an anti-CD33 …

DA: 86 PA: 18 MOZ Rank: 15

ascopubs.org:443

https://ascopubs.org:443/doi/10.1200/JCO.2017.35.15_suppl.e18561

WEBMay 30, 2017. Response to induction or hypomethylating agent therapy among patients with myeloproliferative neoplasms progressing to accelerated or leukemic phase. Authors: …

DA: 9 PA: 36 MOZ Rank: 32

springer.com:443

https://link.springer.com:443/article/10.1007/s11899-014-0199-0

WEBMar 16, 2014 · Kendra Sweet & Jeffrey E. Lancet. 789 Accesses. 15 Citations. Explore all metrics. Abstract. Acute myeloid leukemia (AML) is a heterogenous disease, and the …

DA: 95 PA: 69 MOZ Rank: 42